EyeGene,Inc Logo

EyeGene,Inc

Develops gene/cell therapies for age-related diseases and preventive vaccines.

185490 | KO

Overview

Corporate Details

ISIN(s):
KR7185490000
LEI:
Country:
South Korea
Address:
경기도 의왕시 양지편2로 13 2층, 의왕시

Description

EyeGene, Inc. is a clinical-stage biopharmaceutical company that researches and develops innovative therapeutics, with a primary focus on gene and cell therapy for age-related diseases. The company's pipeline includes EG-Mirotin, a treatment candidate for non-proliferative diabetic retinopathy and dry age-related macular degeneration. EyeGene is also developing preventive vaccines, such as EG-HPV for cervical cancer, utilizing its proprietary EG-Vac adjuvant system to enhance vaccine efficacy. The company is dedicated to creating transformative treatments by advancing biomedical science.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2024-01-10 00:00
주식등의대량보유상황보고서(일반)
Korean 100.2 KB
2024-01-04 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.8 KB
2024-01-03 00:00
주식매수선택권부여에관한신고
Korean 15.1 KB
2024-01-03 00:00
주주총회소집결의
Korean 13.5 KB
2024-01-02 00:00
주식등의대량보유상황보고서(일반)
Korean 92.2 KB
2024-01-02 00:00
주식등의대량보유상황보고서(일반)
Korean 118.7 KB
2024-01-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 21.3 KB
2024-01-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 20.8 KB
2024-01-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 20.7 KB
2024-01-02 00:00
임원ㆍ주요주주특정증권등소유상황보고서
Korean 20.8 KB
2023-12-21 00:00
증권발행결과(자율공시)(제3자배정 유상증자)
Korean 6.1 KB
2023-12-21 00:00
최대주주변경
Korean 38.6 KB
2023-12-14 00:00
주주명부폐쇄기간또는기준일설정
Korean 4.4 KB
2023-12-14 00:00
현금ㆍ현물배당을위한주주명부폐쇄(기준일)결정
Korean 5.8 KB
2023-12-13 00:00
주요사항보고서(유상증자결정)
Korean 31.6 KB

Automate Your Workflow. Get a real-time feed of all EyeGene,Inc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for EyeGene,Inc

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for EyeGene,Inc via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.